Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23844148 | 0.83 | ACACB (0.35) | ACACB | |
| SCHEMBL12413767 | 0.79 | NPSR1 (0.35) | ACACB | |
| SCHEMBL26277348 | 0.76 | GRIN2D (0.33) | ACACBCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL23827948 | 0.74 | GRIN2D (0.33) | ACACBCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL23827944 | 0.74 | GRIN2D (0.33) | ACACBCHRNB2CHRNA4 | |
| SCHEMBL12705012 | 0.74 | — | — | |
| SCHEMBL28632681 | 0.74 | CHRNB2 (0.41) | ACACBCHRNB2CHRNA4 | |
| SCHEMBL17032828 | 0.73 | ACACB (0.38) | ACACBRAB9A | |
| SCHEMBL15490005 | 0.72 | NPSR1 (0.33) | — | |
| SCHEMBL15487498 | 0.72 | ALDH1A1 (0.39) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | ACACB 3353/4885MME 491/4885CHRNB2 4873/4885 |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | ACACB 3353/4885MME 491/4885CHRNB2 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.